Editorial
Epigenetic therapies, still in the midway between facts and fiction
Terapias epigenéticas, todavía a mitad de camino entre la realidad y la ficción
Olga Sánchez-Pernaute
Division of Rheumatology, Jimenez Diaz Foundation University Hospital and Health Research Institute, Autonoma University, Madrid, Spain
Read
4088
Timeswas read the article
2243
Total PDF
1845
Total HTML
Share statistics
array:23 [ "pii" => "S2173574317301296" "issn" => "21735743" "doi" => "10.1016/j.reumae.2017.05.003" "estado" => "S300" "fechaPublicacion" => "2017-11-01" "aid" => "966" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "copyrightAnyo" => "2017" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Reumatol Clin. 2017;13:311-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 427 "formatos" => array:3 [ "EPUB" => 44 "HTML" => 212 "PDF" => 171 ] ] "Traduccion" => array:1 [ "en" => array:19 [ "pii" => "S1699258X17301043" "issn" => "1699258X" "doi" => "10.1016/j.reuma.2017.05.001" "estado" => "S300" "fechaPublicacion" => "2017-11-01" "aid" => "1059" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Reumatol Clin. 2017;13:311-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2782 "formatos" => array:3 [ "EPUB" => 117 "HTML" => 1690 "PDF" => 975 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Epigenetic therapies, still in the midway between facts and fiction" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "311" "paginaFinal" => "312" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Terapias epigenéticas, todavía a mitad de camino entre la realidad y la ficción" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Olga Sánchez-Pernaute" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Olga" "apellidos" => "Sánchez-Pernaute" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173574317301296" "doi" => "10.1016/j.reumae.2017.05.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574317301296?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X17301043?idApp=UINPBA00004M" "url" => "/1699258X/0000001300000006/v1_201710191241/S1699258X17301043/v1_201710191241/en/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2173574317301144" "issn" => "21735743" "doi" => "10.1016/j.reumae.2016.08.003" "estado" => "S300" "fechaPublicacion" => "2017-11-01" "aid" => "1059" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Reumatol Clin. 2017;13:313-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 558 "formatos" => array:3 [ "EPUB" => 60 "HTML" => 341 "PDF" => 157 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Status of Private Rheumatology in Spain" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "313" "paginaFinal" => "317" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Estado de la reumatología privada en España" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 963 "Ancho" => 1727 "Tamanyo" => 89460 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Variation in the genders according to age quartiles. The fourth quartile was divided into <65 years and ≥65 years of age. The right-hand column shows the overall percentages.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Beatriz Yoldi Muñoz, Antonio Gómez Centeno, José Vicente Moreno Muelas" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Beatriz" "apellidos" => "Yoldi Muñoz" ] 1 => array:2 [ "nombre" => "Antonio" "apellidos" => "Gómez Centeno" ] 2 => array:2 [ "nombre" => "José Vicente" "apellidos" => "Moreno Muelas" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X16301036" "doi" => "10.1016/j.reuma.2016.08.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X16301036?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574317301144?idApp=UINPBA00004M" "url" => "/21735743/0000001300000006/v1_201710250854/S2173574317301144/v1_201710250854/en/main.assets" ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Epigenetic therapies, still in the midway between facts and fiction" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "311" "paginaFinal" => "312" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Olga Sánchez-Pernaute" "autores" => array:1 [ 0 => array:3 [ "nombre" => "Olga" "apellidos" => "Sánchez-Pernaute" "email" => array:1 [ 0 => "osanchez@fjd.es" ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Division of Rheumatology, Jimenez Diaz Foundation University Hospital and Health Research Institute, Autonoma University, Madrid, Spain" "identificador" => "aff0005" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Terapias epigenéticas, todavía a mitad de camino entre la realidad y la ficción" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Following the emergence of epigenetics in the research of human disease, great expectations were put in characterizing altered epigenetic pathways as potential targets for therapies. Epigenetic mechanisms are sophisticated networks regulating the expression of genes associated to cell differentiation or to developmental stages. They involve post-translational modifications of histones and genomic cytosines resulting in changes in chromatin conformation.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">1</span></a> Most epigenetic modifications need the active participation of enzymes and cell energetic pathways, and are sensitive to external cues.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">2</span></a> In this way, changes to chromatin conformation can result from exposure to environmental aggressors and account for phenotypic variations of genetic traits. Interestingly, this interaction with environmental factors can be imprinted in cells and individuals, in this way exerting a role on their susceptibility to disease.<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">3</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Different studies have shown evidence of a shared aberrant epigenetic signature identifying early phases of tumorigenesis, while an altered expression of epigenetic enzymes, such as histone methyl transferases (HMT) and demethylases (HDM), is commonly observed in cancer cells.<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">4</span></a> As a result of this insight, a variety of compounds are currently undergoing development and some of them have already been licensed for the treatment of some tumors. Two types of epigenetic mechanisms have been up to now translated to therapeutics, namely inhibitors of DNA methyltransferases (DNMT) and those of histone deacetylases (HDAC). Both strategies render the re-expression of abnormally silenced lineage specific genes and tumor suppressors, in this way facilitating cell differentiation and growth control.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">5</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">A similar approach was enthusiastically conducted in different rheumatic disorders. In the last few years, a vast number of altered epigenetic marks has been described in target cells from patients with these conditions, paving the way for the design of novel therapies.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">6</span></a> A starting hurdle has been to read into some of the contradictory data drawn in different experiments, but on the whole, we are now in a fair position to elaborate theoretical epigenetic models of disease, at least as concerns rheumatoid arthritis and lupus.</p><p id="par0020" class="elsevierStylePara elsevierViewall">As a general overview, rheumatoid synovitis appears to be associated to the silencing of pro-apoptotic molecules, through genomic hypermethylation at differentially methylated regions (DMR) close to their promoters.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">7</span></a> This cancer-resembling signature provides a therapeutic target for the use of DNMT inhibitors. The finding is not surprising, taking that one of the beneficial effects exerted by methotrexate is precisely related to its ability to preclude DNMT1 constitutive activity through the deprivation of S-adenosyl methionine (SAM), which acts as universal donor for methylation reactions.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">8</span></a> An additional interesting target to explore in the disease is the family of histone acetylases (HAT). A local high HAT to HDAC ratio has been consistently found in the microenvironment of rheumatoid synovial tissues as well as in circulating mononuclear cells from the patients. This atmosphere is associated to an open frame conformation of chromatin at nuclear factor kappa B (NFκB) responsive genes, allowing an excessive output of chemokines, adhesion molecules, and some of the pathogenic cytokines of the disease. Interestingly, this unbalanced HAT/HDAC ratio has also been found in the gut of patients with bowel inflammatory disease, and could therefore be taken as a hallmark of dysfunctional inflammation.</p><p id="par0025" class="elsevierStylePara elsevierViewall">As regards epigenetic alterations in lupus, several experimental approaches coincide in demonstrating a combined effect of classical disease triggers, such as UV radiation, hydralazine and procainamide, on lymphocytes.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">9</span></a> On one hand, these agents can block DNMT enzymes, and on the other, they are able to cause DNA damage. Through the former action, target cells increase the expression of immune-reactive factors, and subsequently exhibit a low positive selection threshold. In this sense, T cells from the patients show an abnormally low DNA methylation, particularly during flares, associated to an enhanced expression of costimulatory molecules and interferon responsive elements. In addition, DNMT need to be recruited to regions of DNA damage, where they participate in the DNA repair response (DRR). Therefore, DRR might be compromised in the patients, and this could result in the abnormal persistency of altered chromatin. In turn, chromatin alterations increase its antigenicity. This simple epigenetic model for lupus is quite attractive, since it puts together triggers, cell damage, positive selection and development of anti DNA antibodies which characterize the disease. It also suggests restoration of DNMT enzymes as the principal goal in a hypothetical epigenetic approach of lupus.</p><p id="par0030" class="elsevierStylePara elsevierViewall">But for the use of epigenetic therapies in rheumatic diseases additional hurdles need to be overcome, the first of them being the accessibility of the epigenetic marks needing to be targeted. Although abnormal marks are easier to remove than the constitutive ones, most epigenetic modifications take place during cell division or in stages of high transcriptional activity. In particular, the use of DNMT modifiers could miss low-proliferating cells, unless used at high doses, at which the hazard of off-target demethylation would be high. However, this approach remains a promising option as part of combined therapies.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">10</span></a> On the other hand, the huge number of molecules involved in histone modifications, and their relative specificity for a substrate site, has led to an expansion of the search of inhibitors. Again, a major drawback for targeting histone modifiers is that they bear a high noise-to-signal ratio, not only due to a lack of enzyme specificity, but also because histone modifiers play additional roles in the cell machinery, including the DDR, cell cycle arrest, or activation of cytoplasmic metabolic systems. This issue is of little concern when approaching the treatment of advanced cancer, but more difficult to cope with in inflammatory diseases.</p><p id="par0035" class="elsevierStylePara elsevierViewall">Interestingly, between compounds under scrutiny for therapeutics, some nutrient components have been identified as powerful epigenetic modifiers, and this finding has opened a whole new perspective in the prevention and treatment of cancer.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">11</span></a> Not in vain, a balanced food intake, physical activity and avoidance of obesity is thought to account for a 30% to 40% prevention of cancer cases. Essential nutrients, such as Fe<span class="elsevierStyleSup">2+</span>, Zn<span class="elsevierStyleSup">2+</span> and Mg<span class="elsevierStyleSup">2+</span>, B group vitamins, acetyl coenzyme A, ketoglutarate, NAD+, or S-adenosylmethionine, act as permissive factors for epigenetic modifying enzymes. Accordingly, their deficiency hampers the establishment of physiological epigenetic marks upon cell division. On the other hand, the so called bioactive food components, typically present in vegetables and fruits, can help re-express constitutive genes abnormally silenced, or shut down inducible responses through the activation of histone modifiers.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">12</span></a> The principal nutrients under investigation for their therapeutical properties are methyl donors, Se<span class="elsevierStyleSup">2+</span>, fatty acids and phytochemicals, and between the latter, flavonoids, retinoids, isothiocyanates, and allyl groups. Short chain fatty acids behave as HDAC inhibitors, and some are currently approved for their use in T cell lymphoma, such as the hydroxamic acid vorinostat, or the epoxides romidepsin, and panubinostat, currently used in combination with bortizomib and dexamethasone in recurrent multiple myeloma. Flavonoids are a large family of polyphenols from different sources, including tea, grapes, berries, celery, and a long etcetera, which act as potent inhibitors of DNMT and HAT, but also play roles as detoxifiers, antioxidants, and inhibitors of protein kinases. Some of them appear to confer protection to the development of cancer, although the extent of this action has yet to be firmly established.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">13</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">On the other hand, the effects of an excessive intake of bioactive food components can have unpredictable effects in different settings, and their use as natural cure or prevention of illness should be discouraged until more clear scientific evidence is available. This issue is of particular relevance, due to the increasing habit of people to try natural remedies aspiring to improve their well-being. Considering their ingredients, some of the marketed nourishment complements are literally epigenetic cocktails, and this is probably a major reason for being rated as beneficial. Most of these compounds have unrestricted access to their consume, in spite of lacking enough information about interactions and dosing. Moreover, there is a relative tolerance to misleading advertising claiming beneficial effects, because they are globally regarded as safe. However, quoting Paracelsus, “nothing is without poison; only the dose permits something not to be poisonous”. Natural components are not necessarily beneficial or harmful, but can yield diverse effects depending on the host, and they might incide in different ways in the context of inflammation, degenerative processes and cancer risk.<a class="elsevierStyleCrossRefs" href="#bib0120"><span class="elsevierStyleSup">11,13</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">In summary, the impact of epigenetics on human disease and its potential use in therapeutics is only starting to be unveiled. This field has already shifted our conception of how the environment contributes to both evolutionary and individual adaptation. We have also reasons to believe that healthy habits help us keep our physiological epigenetic marks and even overcome potential alterations imprinted in our cells and thereby fight disease. However, we are still far from being able to use this insight in the prevention and treatment of inflammatory diseases. At this point, having good habits, eating a varied diet, and not trusting promised healing properties of nutrition pills are the best recommendations we can offer our patients when asked for advice on how to deal with their conditions.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:13 [ 0 => array:3 [ "identificador" => "bib0070" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epigenetic inheritance during the cell cycle" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A.V. Probst" 1 => "E. Dunleavy" 2 => "G. Almouzni" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nrm2640" "Revista" => array:6 [ "tituloSerie" => "Nat Rev Mol Cell Biol" "fecha" => "2009" "volumen" => "10" "paginaInicial" => "192" "paginaFinal" => "206" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19234478" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0075" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epigenetics at the crossroads of genes and the environment" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A.P. Feinberg" 1 => "M.D. Fallin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jama.2015.10414" "Revista" => array:6 [ "tituloSerie" => "JAMA" "fecha" => "2015" "volumen" => "314" "paginaInicial" => "1129" "paginaFinal" => "1130" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26372577" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0080" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epigenetics and the environment: emerging patterns and implications" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "R. Feil" 1 => "M.F. Fraga" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nrg3142" "Revista" => array:6 [ "tituloSerie" => "Nat Rev Genet" "fecha" => "2012" "volumen" => "13" "paginaInicial" => "97" "paginaFinal" => "109" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22215131" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0085" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epigenetics in cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M. Esteller" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMra072067" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2008" "volumen" => "358" "paginaInicial" => "1148" "paginaFinal" => "1159" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18337604" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0090" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "W. Timp" 1 => "A.P. Feinberg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nrc3486" "Revista" => array:6 [ "tituloSerie" => "Nat Rev Cancer" "fecha" => "2013" "volumen" => "13" "paginaInicial" => "497" "paginaFinal" => "510" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23760024" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0095" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epigenetics and autoimmunity" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "W.H. Brooks" 1 => "C. Le Dantec" 2 => "J.O. Pers" 3 => "P. Youinou" 4 => "Y. Renaudineau" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaut.2009.12.006" "Revista" => array:6 [ "tituloSerie" => "J Autoimmun" "fecha" => "2010" "volumen" => "34" "paginaInicial" => "J207" "paginaFinal" => "J219" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20053532" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0100" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "6290682" "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The mechanisms underlying chronic inflammation in rheumatoid arthritis from the perspective of the epigenetic landscape" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Y. Araki" 1 => "T. Mimura" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "J Immunol Res" "fecha" => "2016" "volumen" => "2016" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0105" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Low-dose methotrexate inhibits methionine S adenosyltransferase in vitro and in vivo" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Y.C. Wang" 1 => "E.P. Chiang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2119/molmed.2011.00048" "Revista" => array:6 [ "tituloSerie" => "Mol Med" "fecha" => "2012" "volumen" => "18" "paginaInicial" => "423" "paginaFinal" => "432" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22193356" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0110" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impaired DNA methylation and its mechanisms in CD4(+)T cells of systemic lupus erythematosus" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "Y. Zhang" 1 => "M. Zhao" 2 => "A.H. Sawalha" 3 => "B. Richardson" 4 => "Q. Lu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaut.2013.01.005" "Revista" => array:6 [ "tituloSerie" => "J Autoimmun" "fecha" => "2013" "volumen" => "41" "paginaInicial" => "92" "paginaFinal" => "99" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23340289" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0115" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Perspectives on epigenetic-based immune intervention for rheumatic diseases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "S.G. Gray" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/ar4167" "Revista" => array:5 [ "tituloSerie" => "Arthritis Res Ther" "fecha" => "2013" "volumen" => "15" "paginaInicial" => "207" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23510070" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0120" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The interaction between epigenetics, nutrition and the development of cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "K.S. Bishop" 1 => "L.R. Ferguson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/nu7020922" "Revista" => array:6 [ "tituloSerie" => "Nutrients" "fecha" => "2015" "volumen" => "7" "paginaInicial" => "922" "paginaFinal" => "947" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25647662" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0125" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epigenetics: a new bridge between nutrition and health" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S.W. Choi" 1 => "S. Friso" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3945/an.110.1004" "Revista" => array:6 [ "tituloSerie" => "Adv Nutr" "fecha" => "2010" "volumen" => "1" "paginaInicial" => "8" "paginaFinal" => "16" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22043447" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0130" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epigenetic activities of flavonoids in the prevention and treatment of cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "C. Busch" 1 => "M. Burkard" 2 => "C. Leischner" 3 => "U.M. Lauer" 4 => "J. Frank" 5 => "S. Venturelli" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Clin Epigenet" "fecha" => "2015" "volumen" => "7" "paginaInicial" => "64" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735743/0000001300000006/v1_201710250854/S2173574317301296/v1_201710250854/en/main.assets" "Apartado" => array:4 [ "identificador" => "17335" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/21735743/0000001300000006/v1_201710250854/S2173574317301296/v1_201710250854/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574317301296?idApp=UINPBA00004M" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 5 | 9 | 14 |
| 2024 October | 38 | 45 | 83 |
| 2024 September | 31 | 42 | 73 |
| 2024 August | 42 | 54 | 96 |
| 2024 July | 34 | 41 | 75 |
| 2024 June | 35 | 52 | 87 |
| 2024 May | 23 | 59 | 82 |
| 2024 April | 35 | 38 | 73 |
| 2024 March | 34 | 42 | 76 |
| 2024 February | 20 | 38 | 58 |
| 2024 January | 24 | 36 | 60 |
| 2023 December | 21 | 43 | 64 |
| 2023 November | 24 | 37 | 61 |
| 2023 October | 33 | 45 | 78 |
| 2023 September | 46 | 65 | 111 |
| 2023 August | 31 | 44 | 75 |
| 2023 July | 34 | 40 | 74 |
| 2023 June | 28 | 44 | 72 |
| 2023 May | 31 | 48 | 79 |
| 2023 April | 11 | 19 | 30 |
| 2023 March | 33 | 38 | 71 |
| 2023 February | 54 | 40 | 94 |
| 2023 January | 17 | 24 | 41 |
| 2022 December | 48 | 39 | 87 |
| 2022 November | 34 | 40 | 74 |
| 2022 October | 45 | 36 | 81 |
| 2022 September | 30 | 31 | 61 |
| 2022 August | 34 | 42 | 76 |
| 2022 July | 24 | 52 | 76 |
| 2022 June | 32 | 37 | 69 |
| 2022 May | 29 | 36 | 65 |
| 2022 April | 28 | 54 | 82 |
| 2022 March | 34 | 51 | 85 |
| 2022 February | 20 | 32 | 52 |
| 2022 January | 34 | 49 | 83 |
| 2021 December | 32 | 42 | 74 |
| 2021 November | 32 | 39 | 71 |
| 2021 October | 37 | 50 | 87 |
| 2021 September | 24 | 38 | 62 |
| 2021 August | 14 | 44 | 58 |
| 2021 July | 21 | 32 | 53 |
| 2021 June | 15 | 21 | 36 |
| 2021 May | 29 | 39 | 68 |
| 2021 April | 56 | 77 | 133 |
| 2021 March | 24 | 24 | 48 |
| 2021 February | 18 | 19 | 37 |
| 2021 January | 23 | 26 | 49 |
| 2020 December | 21 | 22 | 43 |
| 2020 November | 25 | 18 | 43 |
| 2020 October | 12 | 21 | 33 |
| 2020 September | 33 | 33 | 66 |
| 2020 August | 24 | 21 | 45 |
| 2020 July | 15 | 20 | 35 |
| 2020 June | 19 | 12 | 31 |
| 2020 May | 41 | 14 | 55 |
| 2020 April | 35 | 17 | 52 |
| 2020 March | 7 | 1 | 8 |
| 2020 February | 1 | 0 | 1 |
| 2019 February | 1 | 0 | 1 |
| 2018 July | 2 | 0 | 2 |
| 2018 May | 3 | 1 | 4 |
| 2018 April | 1 | 2 | 3 |
| 2018 March | 12 | 7 | 19 |
| 2018 February | 38 | 19 | 57 |
| 2018 January | 44 | 34 | 78 |
| 2017 December | 49 | 43 | 92 |
| 2017 November | 50 | 55 | 105 |
| 2017 October | 11 | 10 | 21 |
Show all
